Exceptional Clinical Outcomes Shown in Complex, Left-Sided Ablations
Nearly 23,000 Cases Performed with Remote Magnetic Navigation
ST. LOUIS, Aug. 5 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq:
STXS), announced today that clinicians have performed more than 2,500
procedures with the magnetic irrigated catheter since its commercial release.
The clinical performance of the catheter in these cases has been exceptional.
The major adverse cardiac event rate for magnetic procedures remains at 0.1%
"The irrigated tip is a great asset for creating deep lesions in patients
with ventricular tachycardias in the setting of structural heart disease,"
said Dr. Raul Weiss, associate professor of medicine at The Ohio State
University and an electrophysiologist at the Ross Heart Hospital in Columbus.
"The Thermocool magnetic catheter creates deeper lesions because the catheter
remains in contact with the beating heart. The irrigation allows me to
deliver more energy, creating a larger lesion. You don't have to push on the
catheter like you do with a manual catheter, so the likelihood of perforation,
I think, is significantly reduced."
Overall, the Niobe Remote Magnetic Navigation System has been utilized in
nearly 23,000 cases worldwide. These include ablations of a wide variety of
cardiac arrhythmias in all four chambers of the heart and across a broad
spectrum of patients ranging from pediatric to geriatric. Included in the
Niobe clinical experience are several very compelling procedures in patients
with congenital heart defects and patients with peripheral vascular occlusive
disease. Altogether this represents the broadest range of cardiovascular
applications achieved with any commercial remote magnetic, robotic or
mechanical navigation system presently in the marketplace.
"The addition of the magnetic irrigated catheter has broadened the
capabilities of the Stereotaxis system, further demonstrating the potential of
our remote magnetic navigation technology as a platform for all manner of
cardiac and vascular interventions," said Michael P. Kaminski, Stereotaxis
President and CEO. "Stereotaxis labs are quickly becoming the preferred labs
for complex cases at centers across the globe. These include a growing number
of community hospitals, which are using our advanced technology to build
robust electrophysiology practices. With the diverse group of clinicians who
now routinely use our Niobe system, we are particularly delighted that the
system has maintained the safety profile for which it has become well known."
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical
suite to enhance the treatment of coronary artery disease and arrhythmias. The
Stereotaxis System is designed to enable physicians to complete more complex
interventional procedures by providing image guided delivery of catheters and
guidewires through the blood vessels and chambers of the heart to treatment
sites. This is achieved using computer-controlled, externally applied magnetic
fields that govern the motion of the working tip of the catheter or guidewire,
resulting in improved navigation, shorter procedure time and reduced x-ray
exposure. The core components of the Stereotaxis system have received
regulatory clearance in the U.S., Europe, and Canada and elsewhere.
About Forward Looking Statements
This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. Forward-looking statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to,
continued acceptance for the Company's products in the marketplace,
competitive factors, changes in government reimbursement procedures,
dependence upon third-party vendors, and other risks discussed in the
Company's periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the
date of this release. There can be no assurance that we will recognize revenue
related to our purchase orders and other commitments in any particular period
or at all because some of these purchase orders and other commitments are
subject to contingencies that are outside of our control. In addition, these
orders and commitments may be revised, modified or canceled, either by their
express terms, as a result of negotiations, or by project changes or delays.
SOURCE Stereotaxis, Inc.
-0- 08/05/2009
/CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,
+1-314-678-6105; or investors, Doug Sherk & Jenifer Kirtland, +1-415-896-6820,
or media, Steve DiMattia, +1-646-201-5445, all of EVC Group, Inc., for
Stereotaxis, Inc./
/Web Site: http://www.stereotaxis.com /
(STXS)
CO: Stereotaxis, Inc.
ST: Missouri
IN: HEA MTC MEQ
SU: TRI
PR
-- SF56972 --
8572 08/05/200906:30 EDThttp://www.prnewswire.com